scholarly journals Obesity changes the human gut mycobiome

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
M. Mar Rodríguez ◽  
Daniel Pérez ◽  
Felipe Javier Chaves ◽  
Eduardo Esteve ◽  
Pablo Marin-Garcia ◽  
...  
Keyword(s):  
Hdl Cholesterol ◽  
Caproic Acid ◽  
Fungal Species ◽  
Human Gut ◽  
Body Fatness ◽  
Diverse Range ◽  
Obese Subjects ◽  
Metabolically Healthy ◽  
Treatment Of Obesity ◽  
Novel Target

Abstract The human intestine is home to a diverse range of bacterial and fungal species, forming an ecological community that contributes to normal physiology and disease susceptibility. Here, the fungal microbiota (mycobiome) in obese and non-obese subjects was characterized using Internal Transcribed Spacer (ITS)-based sequencing. The results demonstrate that obese patients could be discriminated by their specific fungal composition, which also distinguished metabolically “healthy” from “unhealthy” obesity. Clusters according to genus abundance co-segregated with body fatness, fasting triglycerides and HDL-cholesterol. A preliminary link to metabolites such as hexadecanedioic acid, caproic acid and N-acetyl-L-glutamic acid was also found. Mucor racemosus and M. fuscus were the species more represented in non-obese subjects compared to obese counterparts. Interestingly, the decreased relative abundance of the Mucor genus in obese subjects was reversible upon weight loss. Collectively, these findings suggest that manipulation of gut mycobiome communities might be a novel target in the treatment of obesity.

scholarly journals Circulating Adipokines in Healthy versus Unhealthy Overweight and Obese Subjects

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Assim A. Alfadda
Keyword(s):  
Hdl Cholesterol ◽  
Metabolic Health ◽  
Bioactive Substances ◽  
Metabolically Healthy Obese ◽  
Cholesterol Levels ◽  
Increased Risk ◽  
Obese Subjects ◽  
Healthy Obese ◽  
Metabolically Healthy

It is now well established that not all obese subjects are at increased risk of cardiometabolic complications; such patients are termed the metabolically healthy obese. Despite their higher-than-normal body fat mass, they are still insulin sensitive, with a favorable inflammatory and lipid profile and no signs of hypertension. It remains unclear which factors determine an individual's metabolic health. Adipose tissue is known to secrete multiple bioactive substances, called adipokines, that can contribute to the development of obesity-associated complications. The goal of this study was to determine whether the circulating adipokine profiles differs between metabolically healthy and metabolically unhealthy overweight and obese subjects, thereby obtaining data that could help to explain the link between obesity and its related cardiometabolic complications. We defined metabolic health in terms of several metabolic and inflammatory risk factors. The serum adiponectin levels were higher in the healthy group and showed a positive correlation with HDL cholesterol levels in the unhealthy group. There were no differences between the two groups in the levels of serum leptin, chemerin and orosomucoid. Accordingly, adiponectin might play a role in protecting against obesity-associated cardiometabolic derangements. More studies are needed to clarify the role of different chemerin isoforms in this system.

Gut Mycobiota and Fungal Metabolites in Human Homeostasis

2018 ◽  
Vol 20 (2) ◽  
pp. 232-240 ◽  
Author(s):  
Izabella Mogilnicka ◽  
Marcin Ufnal
Keyword(s):  
Wide Spectrum ◽  
Biological Effects ◽  
Fungal Species ◽  
Fungal Metabolites ◽  
Human Gut ◽  
Fecal Transplantation ◽  
Bacterial Microbiota ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background:Accumulating evidence suggests that microbiota play an important role in host’s homeostasis. Thus far, researchers have mostly focused on the role of bacterial microbiota. However, human gut is a habitat for several fungal species, which produce numerous metabolites. Furthermore, various types of food and beverages are rich in a wide spectrum of fungi and their metabolites.Methods:We searched PUBMED and Google Scholar databases to identify clinical and pre-clinical studies on fungal metabolites, composition of human mycobiota and fungal dysbiosis.Results:Fungal metabolites may serve as signaling molecules and exert significant biological effects including trophic, anti-inflammatory or antibacterial actions. Finally, research suggests an association between shifts in gut fungi composition and human health. Changes in mycobiota composition have been found in obesity, hepatitis and inflammatory bowel diseases.Conclusion:The influence of mycobiota and dietary fungi on homeostasis in mammals suggests a pharmacotherapeutic potential of modulating the mycobiota which may include treatment with probiotics and fecal transplantation. Furthermore, antibacterial action of fungi-derived molecules may be considered as a substitution for currently used antibacterial agents and preservatives in food industry.

scholarly journals Natural Course of Metabolically Healthy Overweight/Obese Subjects and the Impact of Weight Change

Nutrients ◽  
2016 ◽  
Vol 8 (7) ◽  
pp. 430 ◽  
Author(s):  
Ruizhi Zheng ◽  
Chengguo Liu ◽  
Chunmei Wang ◽  
Biao Zhou ◽  
Yi Liu ◽  
...  
Keyword(s):  
Weight Change ◽  
Natural Course ◽  
Obese Subjects ◽  
Metabolically Healthy ◽  
The Impact

Abstract 17843: Visceral Adipose Tissue Secretion of Adiponectin Decreases with Increased Body Mass Index

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Lenore R Rengel ◽  
Brittaney Obi ◽  
Jon Gould ◽  
Matthew Goldblatt ◽  
Andrew Kastenmeier ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Visceral Adipose Tissue ◽  
Metabolic Health ◽  
Metabolically Healthy Obese ◽  
Obese Subjects ◽  
Healthy Obese ◽  
Metabolically Healthy ◽  
Visceral Adipose ◽  
Subcutaneous Adipose

Introduction: Peripheral adiposity is associated with better metabolic health and higher plasma adiponectin (ADPN) levels. Since ADPN is secreted mainly by adipose tissue (AT), it is intriguing that higher visceral adipose tissue (VAT) is associated with lower ADPN levels and poor metabolic health. Hypothesis: We hypothesized that various AT depots differ in their ability to secrete ADPN. Methods: Paired AT samples (VAT and subcutaneous adipose tissue (SAT)) were collected from 19 subjects (10 women, 15 obese) undergoing elective abdominal surgery. The samples were cultured and the supernatant was collected after 24 hours. ADPN levels released into the supernatant from VAT and SAT were measured using multiplex methods. Subjects were defined as obese or non-obese (NO) based on BMI > or ≤ 30kg/m2 respectively. Obese subjects were further classified as metabolically unhealthy obese (MUO) or metabolically healthy obese (MHO) based on presence or absence of type 2 diabetes mellitus, hypertension, or cardiovascular disease at the time of surgery. Results: Mean ADPN secretion levels from SAT and VAT were similar in NO subjects (17.3 ± 3.4 vs. 9.8 ± 13.0 ng/mL/mg, p=0.5) whereas the mean ADPN secretion was lower from VAT among obese subjects (15.9 ± 0.8 vs. 4.5 ± 0.2 ng/mL/mg, p=0.0002). ADPN secretion decreased from VAT (r=-0.16) and increased from SAT (r=0.33) with increased BMI (Fig.1). When MHO and MUO were compared, ADPN secretion from VAT in MHO was reduced only slightly (16.1 ± 8.2 vs. 4.0 ± 2.0 ng/mL/mg, p=0.07) whereas ADPN secretion was significantly reduced in MUO (15.9 ± 5.3 vs. 4.7 ± 4.6 ng/mL/mg, p=0.003). Conclusions: Reduced ADPN secretion from VAT in subjects with increasing BMI may explain lower circulating ADPN levels in obese individuals. Higher ADPN production from SAT and the relatively preserved secretion of ADPN from VAT may explain metabolic health in some obese individuals. Futures studies will help identify factors that control ADPN secretion from AT.

Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects

1995 ◽  
Vol 268 (4) ◽  
pp. E588-E594 ◽  
Author(s):  
J. L. Potts ◽  
S. W. Coppack ◽  
R. M. Fisher ◽  
S. M. Humphreys ◽  
G. F. Gibbons ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Low Density Lipoprotein ◽  
Postprandial Lipemia ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Control Group ◽  
Postprandial Period ◽  
Before And After ◽  
Obese Subjects ◽  
Subcutaneous Adipose

Adipose tissue is an important site of clearance of circulating triacylglycerol (TAG), especially in the postprandial period. Postprandial lipemia is usually increased in obesity. We studied the extraction of TAG from plasma and TAG-rich lipoproteins (TRLs) in subcutaneous adipose tissue in 11 control and 8 obese subjects before and after a mixed meal. Clearance of plasma TAG and very low-density lipoprotein (VLDL)-TAG was decreased in the obese subjects after an overnight fast. After the meal, chylomicron-TAG extraction increased in the control group whereas VLDL-TAG clearance decreased; these changes were not seen in the obese group, in whom the VLDL particles appeared to be better able to compete with the chylomicrons for clearance by lipoprotein lipase. In the control subjects, removal of TAG from the TRL in the postprandial period was accompanied by a shift toward addition of cholesterol to the high-density lipoprotein (HDL) fraction; this was not observed in the obese subjects. We conclude that disturbed TRL-TAG clearance in adipose tissue is related both to the elevated plasma TAG concentrations and the depressed HDL-cholesterol concentrations typical of obesity.

Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists

2017 ◽  
Vol 31 (11) ◽  
pp. 1403-1418 ◽  
Author(s):  
Guy A Higgins ◽  
Fiona D Zeeb ◽  
Paul J Fletcher
Keyword(s):  
Lifestyle Modification ◽  
Conditioned Reward ◽  
Receptor Agonists ◽  
Subsequent Phase ◽  
Obese Subjects ◽  
Clinically Significant ◽  
Treatment Of Obesity ◽  
Phase Ii And Iii ◽  
Modest Effect

The selective 5-HT2C receptor agonist lorcaserin entered clinical obesity trials with the prevalent view that satiety was a primary mechanism of action. Subsequent Phase II and III trials demonstrated efficacy in terms of weight loss, although the overall effect size (~3% placebo-corrected change) is considered modest. Lorcaserin has been approved by the FDA for the treatment of obesity with lifestyle modification, but since its introduction in 2013 its sales are in decline, probably due to its overall modest effect. However, in some individuals, lorcaserin has a much more clinically significant effect (i.e. >10% placebo-corrected change), although what common features, if any, define these high responders is presently unknown. In the present article we highlight the evidence that alternative mechanisms to satiety may contribute to the anti-obesity effect of lorcaserin, namely effects on constructs of primary and conditioned reward and impulsivity. This may better inform the clinical evaluation of lorcaserin (and any future 5-HT2C receptor agonists) to subgroups of obese subjects characterized by overeating due to maladaptive impulsivity and reward mechanisms. One such population might be individuals diagnosed with binge eating disorder.

scholarly journals Hypercortisolaemia and dyslipidaemia in a selected diabetic population

2018 ◽  
Vol 9 (4) ◽  
pp. 143
Author(s):  
Adediji Isaac Oluwole ◽  
Ayodele Ademola Adelakun ◽  
Afolabi Joy Oluwaseyifunmi ◽  
Akinleye Waheed A ◽  
Taiwo Timilehin Darasimi
Keyword(s):  
Total Cholesterol ◽  
Plasma Glucose ◽  
Type Ii Diabetes ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Serum Cortisol ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Obese Subjects

Background: Type II DM and obesity are metabolic disorders characterized by insulin resistance, dyslipidaemia, and metabolic stress. These features were assessed in patients using fasting plasma glucose, fasting lipid profile and serum cortisol as their markers.Materials and methods: Ninety participants were recruited and classified into 3 groups of thirty each – Obese with type II DM, Non-obese with type II DM, non-obese and non-diabetics who served as controls. Anthropometric measures of weight and height were taken using standard procedures and body mass index was calculated thereafter. Blood samples were collected after an overnight fast for the in vitro assay of serum cortisol, plasma glucose, triglycerides, total cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol using enzyme linked immunosorbent assay and colorimetry as appropriate. Data obtained were analyzed statistically using ANOVA and post hoc test for comparison of variables between groups. Pearson’s correlation was performed to assess the relationship between variables and p<0.05 was considered significant.Results: Serum cortisol, plasma glucose, total cholesterol, triglycerides and LDL-cholesterol were elevated while HDL-cholesterol was reduced in both obese and non-obese subjects with type II diabetes mellitus when compared with controls. Cortisol had a significant positive association with plasma glucose, total cholesterol, triglycerides and LDL-cholesterol in obese subjects with type II diabetes mellitus while cortisol had a significant inverse relationship with HDL-cholesterol in both obese and non-obese subjects with type II diabetes mellitus.Conclusion: From this study, we conclude that elevated serum cortisol, a consequence of type II DM, accompanies dyslipidaemia in both obese and non-obese type II DM patients. It could therefore be inferred that ‘diabetic stress’ is the underlying factor of elevated cortisol in this group.

scholarly journals Increased Oxidized High-Density Lipoprotein/High-Density Lipoprotein–Cholesterol Ratio as a Potential Indicator of Disturbed Metabolic Health in Overweight and Obese Individuals

2019 ◽  
Vol 51 (1) ◽  
pp. 24-33
Author(s):  
Jelena M Janac ◽  
Aleksandra Zeljkovic ◽  
Zorana D Jelic-Ivanovic ◽  
Vesna S Dimitrijevic-Sreckovic ◽  
Jelena Vekic ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Metabolic Health ◽  
High Density ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cholesterol Ratio ◽  
Amyloid A ◽  
Potential Indicator ◽  
Metabolically Healthy

AbstractBackgroundWe evaluated the qualitative characteristics of high-density lipoprotein (HDL) particles in metabolically healthy and unhealthy overweight and obese subjects.MethodsThe study involved 115 subject individuals classified as metabolically healthy and unhealthy, as in overweight and obese groups. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to measure oxidized HDL (OxHDL) and serum amyloid A (SAA) concentrations. Lipoprotein subfractions were separated using nondenaturing gradient gel electrophoresis.ResultsAn independent association was shown between increased OxHDL/HDL-cholesterol ratio and the occurrence of metabolically unhealthy phenotype in the overweight and obese groups. The OxHDL/HDL-cholesterol ratio showed excellent and acceptable diagnostic accuracy in determination of metabolic health phenotypes (overweight group, AUC = 0.881; obese group, AUC = 0.765). Accumulation of smaller HDL particles in metabolically unhealthy subjects was verified by lipoprotein subfraction analysis. SAA concentrations did not differ significantly between phenotypes.ConclusionsIncreased OxHDL/HDL-cholesterol ratio may be a potential indicator of disturbed metabolic health in overweight and obese individuals.

scholarly journals Effects of a 3-Week In-Hospital Body Weight Reduction Program on Cardiovascular Risk Factors, Muscle Performance, and Fatigue: A Retrospective Study in a Population of Obese Adults with or without Metabolic Syndrome

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1495 ◽  
Author(s):  
Antonello E. Rigamonti ◽  
Sabrina Cicolini ◽  
Diana Caroli ◽  
Alessandra De Col ◽  
Massimo Scacchi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Weight Loss ◽  
Body Weight ◽  
Weight Reduction ◽  
Hdl Cholesterol ◽  
Muscle Performance ◽  
Weight Reduction Program ◽  
Body Weight Reduction ◽  
Reduction Program ◽  
Obese Subjects

Background. In clinical practice, there is the diffuse conviction that obese subjects with metabolic syndrome may be more difficult to treat. Objectives and Methods. The aim of the present study was that to investigate the effectiveness of a 3-week in-hospital body weight reduction program (BWRP) in a large population of obese subjects with and without metabolic syndrome (n = 1922; 222 men and 1700 women, age range 18–83 yr). Outcomes such as body mass index (BMI), total (TOT) and HDL cholesterol, systolic and diastolic blood pressures (SBP and DBP, respectively), coronary heart disease (CHD) score, fatigue severity score (FSS), and stair climbing test (SCT) time were evaluated before and after the intervention (Δ). A sex-, BMI-, and age-related stratification of the obese population with or without metabolic syndrome was applied. Results. When compared to obese subjects without metabolic syndrome, at the basal conditions, obese subjects had a poorer cardiometabolic profile, as demonstrated by higher triglycerides, TOT-cholesterol, DBP, SBP, and CHD score, and a more compromised muscle performance (evaluated by SCT), associated with more perception of fatigue (measured by FSS). Nevertheless, obese subjects with metabolic syndrome obtained more benefits from BWRP than those without metabolic syndrome for some outcomes (i.e., ΔTOT-cholesterol, ΔSBP, and ΔCHD score). Despite these differences, the BWRP-induced weight loss was similar between the two groups (i.e., ΔBMI) as well as the gain of muscle performance (i.e., ΔSCT) and the reduction of fatigue (i.e., ΔFSS). Interestingly, the potentially deleterious fall in HDL-cholesterol levels after BWRP was less evident in obese subjects with metabolic syndrome than those without metabolic syndrome. When pooling all data, the ΔCHD score was associated with age, sex, and metabolic syndrome. The remaining outcomes, such as ΔBMI, ΔFSS, and ΔSCT time, were associated with sex and age but not with metabolic syndrome. Finally, ΔBMI was positively correlated with ΔCHD score, ΔFSS, and ΔSCT time in both obese subjects without metabolic syndrome and obese subjects with metabolic syndrome. Conclusions. When comparing obese subjects undergoing a BWRP, metabolic syndrome is not a negative predictive factor affecting the effectiveness of this intervention in terms of weight loss, muscle performance, and psychological well-being.

Sign in / Sign up

Export Citation Format

Share Document